Translational Research on Solid Tumors, Second Edition

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1412

Special Issue Editors


E-Mail Website
Guest Editor
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST) , via P. Maroncelli 40, 47014 Meldola, Italy
Interests: molecular biology; oncology; translational research; next-generation sequencing
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), via P. Maroncelli 40, 47014 Meldola, Italy
Interests: molecular biology; oncology; translational research; liquid biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, there has been more focus on personalization in the treatment of solid tumors, gradually orienting itself towards what is defined as precision medicine. Tumor molecular characteristics, tumor microenvironment composition, and other patient characteristics heavily affect the prognosis and response to therapy. Moreover, for many types of cancers, tumor molecular characterization represents the starting point for making treatment decisions. Moreover, the heterogeneity of the tumor and its evolution during treatment have led to the use of alternative and non-invasive methods for molecular characterization, such as liquid biopsy.

For the current Special Issue, we invite contributions which showcase the latest research in terms of tumor and microenvironment molecular characterization in relation to prognoses and responses to therapy, while also focusing on the use of non-invasive methods for molecular characterization.

This Special Issue will include (but is not limited to) papers on the following topics:

  • Prognostic biomarkers;
  • Tumor heterogeneity;
  • Resistance mechanisms to therapy;
  • Tumor microenvironment;
  • Liquid biopsy;
  • Epigenetics;
  • Targeted therapy;
  • Immunotherapy.

Dr. Paola Ulivi
Dr. Milena Urbini
Dr. Giorgia Marisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • translational research
  • oncology
  • liquid biopsy

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1238 KiB  
Review
Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment
by Shuting Wang, Yuxi Zhu, Shi Du and Yunsi Zheng
Cells 2024, 13(7), 568; https://0-doi-org.brum.beds.ac.uk/10.3390/cells13070568 - 24 Mar 2024
Viewed by 1202
Abstract
Solid tumors, with their intricate cellular architecture and genetic heterogeneity, have long posed therapeutic challenges. The advent of the CRISPR genome editing system offers a promising, precise genetic intervention. However, the journey from bench to bedside is fraught with hurdles, chief among them [...] Read more.
Solid tumors, with their intricate cellular architecture and genetic heterogeneity, have long posed therapeutic challenges. The advent of the CRISPR genome editing system offers a promising, precise genetic intervention. However, the journey from bench to bedside is fraught with hurdles, chief among them being the efficient delivery of CRISPR components to tumor cells. Lipid nanoparticles (LNPs) have emerged as a potential solution. This biocompatible nanomaterial can encapsulate the CRISPR/Cas9 system, ensuring targeted delivery while mitigating off-target effects. Pre-clinical investigations underscore the efficacy of LNP-mediated CRISPR delivery, with marked disruption of oncogenic pathways and subsequent tumor regression. Overall, CRISPR/Cas9 technology, when combined with LNPs, presents a groundbreaking approach to cancer therapy, offering precision, efficacy, and potential solutions to current limitations. While further research and clinical testing are required, the future of personalized cancer treatment based on CRISPR/Cas9 holds immense promise. Full article
(This article belongs to the Special Issue Translational Research on Solid Tumors, Second Edition)
Show Figures

Figure 1

Back to TopTop